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Background: Higher cost and side effects made of some anticholesterol drugs used 
in long time are the reasons why some people change to herbal therapies. Tamarind 
(Tamarindus indica) leaves is one of the herbal therapies. This research aims to determine 
hypolipidemic effect and antioxidant activity of extract of tamarind leaves (ETL).
Methods: We used 25 rats as samples, divided into five groups of negative control 
(CMC 0.5%), positive control (Ezetimibe 1.26 g/kgBW)), first, second and third dose 
of ETL consequently are 0.93, 1.86 and 3.73 g/kgBW.
Results: Paired-samples T-test showed ETL significantly decreased total cholesterol 
(TC), triglyceride (TG) level, and  high-density lipoprotein cholesterol (HDL-C) level 
significantly increased compared with negative control groups (p≤0.05). Low-density 
lipoprotein cholesterol (LDL-C) level had significant difference only at second dose of 
ETL (p<0.05). Furthermore, the data’s difference between pre- and post-intervention 
were analyzed with one-way ANOVA test in TC, TG, and HDL-C level, ETL had a 
significant difference (p≤0.05), while there was no significant difference in LDL -C 
between groups (p>0.05). Data were also analyzed by Post Hoc test. TC, TG, and 
HDL-C level had a significant difference between all variance ETL’s doses and positive 
control compared with negative control group (p≤0.05). For antioxidant activity, ETL 
exhibited the significant reduction in the levels of malondialdehyde (MDA) by paired-
samples T-test (p≤0.05) but there was no significant difference in both of MDA and 
superoxide dismutase (SOD) level (p>0.05) analyzed by One-way ANOVA test. 
Conclusion: All variant of ETL’s doses have hypolipidemic effect and antioxidant activity. 
ETL also has similar effect with Ezetimibe. Saponin, flavonoid, epicatechin, tanin, and 
polyphenol that is contained likely contribute to these pharmacologic effects.   
(Indonesian J Cardiol. 2017;38:72-80)
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Latar Belakang: Tingginya biaya dan efek samping yang ditimbulkan dari beberapa obat antikolesterol yang digunakan dalam jangka waktu 
lama menjadi faktor pendorong meningkatnya penggunaan obat herbal. Salah satu obat herbal yang digunakan adalah daun asam jawa (Tama-
rindus indica). Tujuan penelitian adalah menilai efek hipolipidemik dan aktivitas antioksidan ekstrak daun asam jawa (EDAJ).
Metode: Sampel yang digunakan berjumlah 25 ekor tikus yang dibagi ke dalam lima kelompok yakni kontrol negatif (CMC 0,1%), kontrol 
positif (Ezetemibe), EDAJ dosis-1, dosis-2, dan dosis-3 berturut-turut 0,93 g/kgBB,1,86 g/kgBB), dan 3,73 g/kgBB).
Hasil: Paired-samples T-test menunjukkan EDAJ menurunkan kadar total kolesterol (TC) dan trigliserida (TG) sementara kadar high-density 
lipoprotein cholesterol (HDL-C) meningkat secara signifikan (p≤0,05). Dan kadar low-density lipoprotein cholesterol (LDL-C) menunjukkan 
adanya perbedaan secara signifikan hanya pada EDAJ dosis-2 (p≤0,05). Selanjutnya, selisih data intervensi dianalisis menggunakan uji One-way 
ANOVA. Dari kadar TC, TG, dan HDL-C, EDAJ memiliki perbedaan signifikan di antara kelompok tersebut (p≤0,05), sementara tidak ada 
perbedaan signifikan (p>0,05) pada kadar LDL-C. Selisih data intervensi TC, TG, dan HDL dianalisis dengan Post-Hoc Test dan didapatkan 
adanya perbedaan yang signifikan di antara kelompok kontrol negatif dengan kontrol positif dan seluruh variasi dosis EDAJ (p≤0,05). Da-
lam hal aktivitas antioksidan, dengan Paired-Samples T-Test diketahui bahwa EDAJ memiliki perbedaan penurunan kadar malondialdehida 
(MDA) secara signifikan (p≤0,05), namun baik kadar MDA dan superoksida dismutase (SOD) tidak memiliki perbedaan yang signifikan jika 
dianalisis dengan uji One-way ANOVA (p>0,05). 
Kesimpulan: Seluruh variasi dosis EDAJ memiliki efek hipolipidemik dan aktivitas antioksidan. EDAJ memilki efek yang sama dengan 
Ezetimibe. Saponin, flavonoid, epicatechin, tanin, dan polifenol yang dimiliki berkontribusi terhadap timbulnya efek farmakologi.
(Indonesian J Cardiol.  2017;38:72-80)
Kata kunci: ekstrak daun asam jawa (EDAJ), efek hipolipidemik, aktivitas antioksidan
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Introduction
According to World Health Organization, there are around 58 million deaths in the world in 2005, with 17.5 million of them (30%) due to cardiovascular diseases and 
specifically by heart attacks caused 7.6 million deaths 
(13%).1,2 Riskesdas 2007 showed that the prevalence 
for cardiovascular disease in Indonesia is 7.2% while 
the percentage for ischemic heart disease at all age was 
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Methods
The materials used for this study are tamarind leaves 
obtained from Balai Penelitian Tanaman Rempah dan 
Obat-Bogor which turned into ETL. This extract is 
divided into three doses: 1st dose=0.93 g/KgBW; 2nd 
dose=1.86 g/KgBW, and 3rd dose=3.73 g/KgBW.
Samples used in this study are albino rats (Rattus 
norvegicus), wistar strain, male, age 8 weeks, 200-250 
gram in weight. Male albino rats obtained from Bo-
gor Agricultural University, matching the inclusion 
criteria. This study has been approved by the ethics 
committee of Universitas Pembangunan Nasional 
“Veteran”, Jakarta.
On day 8 through day 22, rats were induced with 
hypercholesterol feeds and distilled water as their 
drinking water. Hypercholesterol feeds were done 
by mixing standard feeds as much as 8 kg added 
with boiled duck egg yolk (400 g), goat fats (800 
g; thawed by boiling), and sufficient amount of hot 
water for 7 days. One rat was given 50 g of hyper-
cholesterol diet, once per day (modified from Gani, 
et al’s research).17
On day 24, rats were given hypercholesterol feeds 
and intervention for 2 weeks according to its group, 
which are: (1) group I: CMC solution; (2) group II: 
Ezetimibe 1.26 g/KgBW/day; (3) group III/1st dose 
ETL 0.83 g/KgBW/day; (4) group IV/2nd ETL: 1.86 g/
KgBW/day; (5) group V/3rd ETL 3.73 g/KgBW/day.
On day 33 blood examination were tested as post 
intervention data.
Biochemical analysis
Biochemical analysis was tested on day 7 (pre-hyper-
cholesterol feed) and day 21 (post-hypercholesterol 
feed/pre-intervention) by taking 3 cc of blood from 
caudal vein rats. On day 35 (post-intervention) by 
taking 6 cc of blood from the heart without anti-
coagulant for lipid profile test and with anti-coagulant 
for antioxidant test. Sample then centrifuged with the 
speed of 1000 rpm for 10 minutes.
Assessment of hypolipidemic effect from ETL
Lipid profile were measured by using automatic ana-
lyzer standard kit.17 Standard serum used for calibra-
tion before each parameter was analyzed.18 For the 
biochemical analysis, the plasma was separated from 
the blood by centrifugation at room temperature for 
around 5.1% from the total percentage of cardiovas-
cular disease.1
Ischemic heart disease or better known as coronary 
heart disease (CHD) is caused by the formation of 
plaque, vascular remodeling, both acute and chronic 
luminal obstruction, blood flow abnormality and 
decline oxygen supply to target organs.3
According to the study of Framingham in Ath-
erosclerosis Risk in Communities, and the study of 
Honolulu there are risk factors in the occurrence of 
CHD, i.e.: age, family history, dyslipidemia, cigarette 
smoking, hypertension, and diabetes.4 The continu-
ity of dyslipidemia formation is correlated with the 
incident of CHD i.e. increase triglyceride level and 
decrease cholesterol HDL level will indirectly increase 
the level of total cholesterol.5
Pharmacologic therapy usually aimed to lower 
cholesterol-LDL level, triglyceride, or increase HDL.6 
Drugs from statin groups in Indonesia are the best 
cholesterol-lowering drugs. Despite statin, there also 
another group from hypocholesterol agent called 
Ezetemibe. Ezetemibe therefore has an important 
role in pharmacological lipid modification.7 However, 
Ezetemibe having lesser adverse effect than statin.8 
Gastrointestinal disruption and other complaint like 
headache is the most adverse effect from Ezetemibe,9 
meanwhile statin groups adverse effects are gastroin-
testinal disruption and hepatotoxic effect.10 Ezetemibe 
has less number of research for hypocholesterol agent as 
a control group done than statin in Indonesia. Higher 
cost and side effects after used in long time are the rea-
sons why some people change to herbal therapy.11,12 
One of the herbal therapy that has been used em-
pirically in lowering blood cholesterol level is Tamarind 
(Tamarindus indica). Tamarind leaves has been known 
to contain compound like tannin, alkaloid, saponin, 
sesquiterpenes, and tannin through phytochemical 
tests.12 Extract of Tamarind Leaves (ETL) in control-
ling lipid profile levels is the effect of saponin action to 
inhibit lipid absorption in intestine.13,14 Saponin levels 
in ETL (in ethanol 70%) are higher than flavonoid 
levels.15 Thus, ETL which contained more saponin has 
a mechanism similar to Ezetemibe as a positive con-
trol. Meanwhile, statin inhibit HMG-CoA reductase 
and has no effect in inhibition of lipid absorption 
in intestine.16  This research is to compare it with a 
positive control group which has no difference in their 
mechanism of action. We aimed at learning more on the 
hypolipidemic effect and antioxidant activity of ETL in 
hyper cholesterol-fed rats compared to Ezetimibe.
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15 min.19 Level of every examination declared in mil-
ligram per deciliter (mg/dL).20
Assessment of antioxidant activities from ETL
Assessment of the antioxidant activities collected from 
MDA level measurement and SOD. MDA level de-
termine lipid per oxidation level.
Principal measurement using Thiobarbituric Acid-
Reacting Substances (TBARS) method on wave length 
of 532 nm. MDA blood concentration declared as 
nmol/mL serum.20 SOD level according to the rate of 
inhibition from ferri- (Fe3+) cytochrome c reductase 
by superoxide anion produced by xanthine/xanthine 
oxidase. Xanthine oxidized to uric acid, while superox-
ide anion which later formed will reduce ferri- (Fe3+) 
cytochrome c. Reduction of ferri- (Fe3+) cytochrome 
c was observed according to the increase absorbance 
on wave length of 550 nm.21
Statistical analysis
First, the data was analyzed with Shapiro Wilk Test 
as normally distributed test. If the data is normally 
distributed then Analysis of Variance (ANOVA) test 
is proceed to show the significant differences between 
groups. Furthermore, the data was tested using Post-
Hoc Test to show exactly how significant the differ-
ences between two groups in a row (confidence degree 
95% with score p ≤0.05).22
Results
All groups were given hypercholesterol feeds for 2 
weeks. Mean value lipid profile for 2 weeks shown in 
Table 1. According to Paired Samples T-Test, there 
were significant increase of TC, TG, LDL-C level and 
decrease of HDL-C level in all groups (p≤0.05). The 
intervention is started by giving hypercholesterol feeds 
and Ezetimibe 1.26 g/KgBW as positive control and 
three ETL dose variations for 2 weeks. After 2 weeks, 
lipid profile examination was repeated. The lipid 
profile data before and after intervention is shown in 
Figure 1 and Table 2.
Hypercholesterolemics rats treated with ETL 
exhibited significant decrease of TC level (p≤0.05) in 
all group except negative control group (by Paired-
samples Test). Furthermore by One-way ANOVA test 
also resulted in significant difference between groups 
compared with negative control groups (p≤0.05). The 
highest decline was seen in the 1st dose ETL (0.93 g/
KgBW) as much as 43.3 mg/dL.
There were significant decreases of TG level 
(p≤0.05) in all groups except negative control group 
(by Paired-samples Test). One-way ANOVA test also 
had resulted in significant difference between groups 
compared with negative control group (p≤0.05). The 
highest decline was seen in the 1st dose ETL (0.93 g/
KgBW) as much as 51.6 mg/dL.
Mean value of LDL-C level significantly 
decreased only in the 2nd dose ETL group (p≤0.05) 
Table 1. Lipid profile after hypercholesterol feeds for 2 weeks. 
Parameter TC (mg/dl) TG (mg/dl) LDL-C (mg/dl) HDL-C (mg/dl)
Before After Before After Before After Before After
Negative
Control
(CMC 0.5 %)
58.00 ± 
10.20
96.60 ± 
8.59*
98.60 ± 
16.21
105.80 ± 
5.68
17.12 ± 
11.35
17.32 ± 
10.35
59.20 ± 
4.97
55.60 ± 
6.91*
Positive
Control (Ezetimibe 1.26 
g/KgBW)
59.00 ± 
3.54
96.00 ± 
3.94*
105.60 ± 
8.26
110.40 ± 
5.46 *
16.20 ± 
6.43
29.32 ± 
10.71*
54.00 ± 
6.17
44.60 ± 
8.35*
1st dose ETL (0.93 g/
KgBW)
58.00 ± 
6.87
97.80 ± 
6.87*
91.60 ± 
16.37
107.20 ± 
8.63
13.92 ± 
13.67
26.56 ± 
7.77*
52.80 ± 
7.76
46.40 ± 
13.72*
2nd dose ETL (1.86 g/
KgBW)
55.00 ± 
2.92
89.60 ± 
6.58*
90.20 ± 
12.47
90.80 ± 
7.12*
18.69 ± 
9.18
25.64 ± 
4.90*
55.80 ± 
8.17
45.80 ± 
8.17*
3rd dose ETL (3.73 g/
KgBW)
55.20 ± 
4.50
89.40 ± 
10.43*
97.80 ± 
13.47
109.40 ± 
10.47*
16.12 ± 
14.51
35.64 ± 
3.03*
51.40 ± 
8.23
47.60 ± 
8.01*
TC=total cholesterol; TG=triglyceride; LDL-C=low density lipoprotein-cholesterol; HDL C=high density lipoprotein-cholesterol; ETL=extract of tamarind 
leaves; a=significance (p≤0.05) in comparison to the negative control group; b=significance (p≤0.05) in comparison to the positive control group. 
*Significance (p≤0.05) before and after intervention.
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Table 3. Antioxidant activities of ETL
Parameter
MDA (µMolar)
SOD
(Unit/ml)
Pre-intervention Post-intervention Diff. Post-intervention
Negative control (CMC 0.5 %) 10.70 ± 3.24 8.82 ± 7.14 1.88 133.58 ± 18.09
Positive control (Ezetimibe 1.26 g/KgBW) 13.65 ± 2.28 6.61 ± 1.44* 7.04 175.84 ± 19.33
1st dose ETL (0.93 g/KgBW) 13.06 ± 1.95 6.93 ± 1.17* 6.13 183.90 ± 18.02
2nd dose ETL (1.86 g/KgBW) 12.79 ± 1.50 5.96 ± 0.89* 6.83 143.51 ± 12.65
3rd dose ETL (3.73 g/KgBW) 17.42 ± 9.94 6.08 ± 3.24* 11.34 166.57 ± 22.80
MDA=malondialdehyde; SOD=superoxide dismutase; ETL=extract of tamarind leaves; a=significance (p≤0.05) in comparison to the negative 
control group; b=significance (p≤0.05) in comparison to the positive control group.
*Significance (p≤0.05) before and after intervention.
Figure 1. The effects of extract of tamarind leaves (ETL) on lipid profile after 
hypercholesterol feeds induction.
TC=total cholesterol; TG=triglyceride; LDL-C=low density lipoprotein-cholesterol; HDL-C=high 
density lipoprotein-cholesterol; negative control=CMC 0.5%; Positive Control=Ezetimibe 1.26g/KgBW; 
ETL=extract of tamarind leaves; 1st dose=0.93 g/KgBW, 2nd dose=1.86 g/KgBW; 3rd dose=3.73 g/KgBW; 
a=significance (p≤0.05) in comparison to the negative control groups; b=significance (p≤0.05) in 
comparison to the positive control groups.
*Significance  (p≤0.05) before and after intervention (Paired-samples test).
Table 2. Mean of the lipid profile level after intervention
Parameter TC (mg/dl) TG (mg/dl) LDL-C (mg/dl) HDL-C (mg/dl)
Before After Diff. Before After Diff. Before After Diff. Before After Diff.
Negative 
Control (CMC 
0.5 %)
96.60 ± 
8.59
86.40 ± 
3.29 
10.2 105.80 ± 
5.68
90.40 ± 
11.86
15.4
26.32 ± 
5.37
25.68 
±8.71
0.64
54.00 ± 
5.87
55.00 ± 
5.29
1
Positive Control
(Ezetimibe 1.26 
g/KgBW)
96.00 ± 
3.94
62.40 ± 
8.38 *a
33.6 
a 110.40 ± 
5.46
76.00 ± 
6.51 *a
34.4 a
34.84 ± 
10.02
25.8± 
5.82
9.04 39.00  
± 8.60
58.20 ± 
5.80*a
19.2a
1st dose ETL 
(0.93 g/KgBW)
97.80 ± 
6.87
54.40 ± 
6.11*a
43.4 
a
107.20 ± 
8.63
55.60 ± 
2.87 *a
51.6 a
40.92 ± 
5.09
32.08 ± 
8.02
8.84 35.40 ± 
6.16
54.60 ± 
3.04*a
19.2 a
TC=total cholesterol; TG=triglyceride; LDL-C=low density lipoprotein-cholesterol; HDL C=high density lipoprotein-cholesterol; ETL=extract of tamarind leaves; 
a= significance (p≤0.05) in comparison to the negative control group; b= significance (p≤0.05) in comparison to the positive control group; Diff = difference.
*Significance (p≤0.05) before and after intervention.
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(by Paired-samples Test). Further One-way ANOVA 
test did not found significant difference between 
groups (p>0.05). And the highest decline was found 
in 2nd dose ETL (1.86 g/KgBW) group as much as 
11.76 mg/dL.
There were significant increases of HDL-C level 
in all groups (p≤0.05) except negative control groups 
(by Paired-samples Test). Further One-way ANOVA 
test also shown significant difference between groups 
compared with negative control group (p≤0.05). The 
highest increase was found in the 3rd dose ETL (3.73 
g/KgBW) group as much as 20 mg/dL.
Antioxidant activities showed by MDA and SOD 
level. MDA level marked the occurence oxidative stress, 
higher level of MDA similar with higher oxidative 
stress in the cell. Based on the mean of MDA level 
before and after intervention, there were significant 
decrease in MDA level on every groups (p≤0.05) except 
negative groups and there was no significant difference 
in all groups (p≥0.05). The lowest MDA decline was 
found in the 3rd dose of  ETL (3.73 g/KgBW), as 
much as 11.34 µMolar (Table 3). 
While for the purpose to fight against advanced 
oxidation is shown by the presence of activity from 
SOD. Higher level of SOD simil ar with higher an-
tioxidant activity in the cell. Based on the results of 
this studies, the highest SOD level was found in the 
1st dose of ETL (0.93 g/KgBW) as much as 183.90 ± 
18.02 unit/ml. And there was no significant difference 
in all groups (p>0.05) (Table 3).
Discussions
Hypolipidemic effect
There were significant TC and TG level decreases, 
and HDL-C increases in all groups except negative 
group. Saponin, flavonoid, epicatechin contained in 
ETL are likely contributed to hypolipidemic effect. 
Saponin in tamarind leaves will bind with bile acid 
and form a large mixed-micelle resulting in failure 
of absorption of cholesterol in the micelle by the mi-
crovilli on the surface of epithelial intestine, resulting 
in the decrease of total plasma cholesterol level.12,13.14 
Flavonoid will increase activation of LDL-C recep-
tor in liver and makes the clearance of LDL-C faster 
therefore the TC level will decrease because of this 
mechanism.26 Epicatechin in tamarind leaves will de-
crease TG level and also increase the clearance of free 
fatty acid and sterol acid through feces.27 Meanwhile 
Ezetimibe specifically works as competitive inhibi-
tor in cholesterol absorbtion with cholesterol carrier 
(protein Niemann-Pick C1 like 1) in epithelial cells 
of small intestines.8,10
In our study, there was no significant difference 
between LDL-C level. For the 1st dose of ETL, the dif-
ference between LDL-C levels was lower than the 2nd 
dose of ETL. This is because the relationship between 
pharmacological responses and drug doses can be ex-
plained as follows: Increase doses in logarithmic scale 
followed by increased pharmacological responses.23 
Linear relationships also occur between drug doses and 
active concentrations of drugs in serum.24
Pharmacological activity of natural medicinal in-
gredients (herbal medicines), just like synthetic drugs, 
is determined by the presence of such drug bonds with 
receptors. The magnitude of the pharmacological in-
tensity depends on the concentration/number of drugs 
reaching the receptor and the type of drug-receptor 
bond, which can be both specific and non-specific. 
The duration of pharmacological effects depends on 
the length of the drug remains in the receptor. For 
natural remedies with large clearances, duration time 
in the body is shorter than that of natural remedies 
that have small clearances. It is used as one of the basic 
doses of natural medicine. The relationship between 
hypothetical drug concentrations in serum with prob-
ability of response and toxicity.23
For the 3rd dose of ETL, there was no difference in 
LDL-C reduction with the 2nd dose of ETL. This may 
Figure 2. The relationship between drug concentration in 
serum and probability response or toxicity.23,24
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be due to an interaction of a chemical compound in 
the form of an antagonist mechanism, in which one 
compounds neutralize the other compound by pro-
ducing the opposite effect on the same physiological 
conditions.25
Antioxidant activity
Flavonoid, polyphenol, and tannin contained in 
ETL plays a role as antioxidant. These agents work 
by increasing antioxidant enzymes activity such as 
glutathione peroxidase  (GPx), catalase (CAT), and 
SOD making lipid difficult to oxidize and prevent 
the formation atherogenic plaque.28  MDA level will 
decrease and SOD level will increase because of this 
mechansim. These facts were supported by RuiLi Yang, 
M.S et al whom mentions that atherosclerosis decrease 
by antioxidant correlates with the decrease MDA level 
in blood.29
This study also found that ezetimibe can decrease 
oxidative stress as seen on the significant decrease of 
MDA level before and after intervention. In contrast, 
Pandaya et al said that Ezetimibe does not significantly 
decrease the MDA level but increases SOD signifi-
cantly. 30
Conclusion
All ETL dose variants have hypolipidemic effect and 
antioxidant activity which play role against hyper-
cholesterolemic condition. ETL also have the same 
effect with Ezetimibe. Saponin, flavonoid and tannin 
are the contents suspected to have pharmacological 
effect in improving lipid profile. Ezetimibe may play 
a role as antioxidant.
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